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ABSTRACT
Objectives: The objectives of this study were twofold: 1)
to evaluate the construct validity of the Treatment Satis-
faction Questionnaire for Medication (TSQM v. II) using
structural equation modeling (SEM); and 2) to assess its
concurrent validity using medication adherence criteria.
Methods: Pharmacy patients ﬁlling a new medication
prescription (n = 342) were recruited from 14 Michigan
pharmacies to participate in a 4-week treatment satisfac-
tion study. The TSQM v. II was tested for model ﬁt
against an established theoretical model (the Decisional
Balance Model of Treatment Satisfaction) using hierarchi-
cal conﬁrmatory factor analysis (HCFA). Regression and
discriminant analytic models were used to examine the
criterion-related validity of the measure.
Results: An exploratory factor analysis, used for TSQM
v. II item reduction, revealed a strongly dimensional
instrument (Effectiveness, Side Effects, and Convenience)
and explained 88% of total pooled variance. Results of an
HCFA using the ﬁnal TSQM v. II items suggested a good
model ﬁt with the data (P > 0.54). In support of concur-
rent validity, the TSQM scales explained between 9% and
20% of the variance in dosing adherence and 60% of the
variance in the likelihood of future use. Discriminant
analysis demonstrated the superior classiﬁcation power of
the hierarchical model of treatment satisfaction over the
discrete attribute model when predicting medication dis-
continuation.
Conclusions: The TSQM v. II has equivalent measure-
ment characteristics as the TSQM v. I, yet uses four fewer
items and more consistent wording. The value of the
Decisional Balance Model for estimation of dosing
adherence and medication persistence over time is
discussed.
Keywords: compliance, medication adherence, patient
reported outcomes, patient satisfaction, psychometric val-
idation, structural equation model, treatment satisfaction.
Introduction
When evaluating the quality of programs, services,
and products, patient satisfaction is a useful patient
reported outcome (PRO). It serves four interrelated
but distinct purposes, permitting: 1) evaluation of
the acceptability of care or treatments from the
patients’ perspective; 2) comparison of health-care
programs or treatment options; 3) identiﬁcation of
service or treatment approaches that require
change; and 4) screening of patients who are likely
to become nonadherent to care plans or medication
regimens [1]. For these reasons, satisfaction meas-
ures are often used to plan health-care delivery sys-
tems and develop pharmaceutical products or
medical devises [2–4]. Because of the breadth of
treatment contexts in which such measures are
used, the survey content of patient satisfaction
measures is highly varied. As a result, at least one
attempt has been made to cluster patient satisfac-
tion measures based on the type of treatment
experiences patients are asked to evaluate (e.g., sat-
isfaction with medication, TS-M; satisfaction with
medical device, TS-D, etc.) [5].
This article reports on the reﬁnement and cross-
validation of the Treatment Satisfaction Question-
naire for Medication version II (TSQM v. II). The
original TSQM v. I was designed as a general meas-
ure of treatment satisfaction with medication (TS-
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M), suitable for use across a wide variety of medi-
cation types and illness conditions. Early develop-
ment research, employing heterogeneous sampling
across different chronic disease states, showed the
TSQM v. I effectively operationalized the three most
common dimensions on which patients’ evaluate
their medication (i.e., medication effectiveness, side
effects of use, and convenience of use) [5]. In addi-
tion, there was preliminary evidence that an overall
satisfaction rating, one that represented individual’s
balanced judgment across all three speciﬁc treat-
ment attributes might be the most predictive indi-
cator of patient satisfaction and adherence [6].
It is important to acknowledge that our focus on
medication attributes is not a universally accepted
standard. Others have proposed that satisfaction
measures include questions about both the predic-
tors and causal consequences of a patients’ treatment
experience. As a result, measures with hybrid causal
structures often include questions on such topics as:
the degree to which individuals’ prior expectations
for a medication are met [7], patients’ willingness to
recommend a medicine to others, and respondents’
willingness to take a medication again [8–10]. It is
our contention, however, that the inclusion of such
predicating or consequential content reduces the pre-
cision of TS-M measures by blurring distinctions
between more distally related causes and effects of
TS-M. Perhaps the most problematic consequence is
that poor measurement distinctions between caus-
ally related constructs impede conceptual advances
with respect to prediction of the behavioral sequelae
of patients’ medication experiences.
Determinants of  Treatment Satisfaction
Because of commercial interests in consumers’ val-
uation of their product experiences, marketing
research literature provides many of the better-
developed satisfaction assessment methodologies
[11], whereas the psychology disciplines typically
provide the theoretical basis for such activities [12].
A number of theoretical perspectives have been
used to describe TS-M. Common to all of these,
treatment satisfaction ratings are thought to be atti-
tudinal responses arising from value judgments that
patients make concerning speciﬁc treatment experi-
ences and clinical encounters [13]. Thus, the core
of the TS-M construct is the patients’ evaluation
of the attributes of their medication. Although
patients’ prior expectations about medication per-
formance, past medication experience, relationship
with the treating clinician, and level of medical
knowledge are all thought to inﬂuence TS-M rat-
ings; the measurement focus of TS-M is to charac-
terize patients’ assessment of their immediate
treatment experiences.
Consequences of  Treatment Satisfaction
A major consequence of patients’ satisfaction or dis-
satisfaction with treatment is future product use.
Satisfaction with medication attributes has been
found to affect patients’ dosing adherence and per-
sistence with treatment over time. Such attributes
include: the degree to which treatment is viewed as
effective and reducing a threat to one’s current or
future health; the perception that a medication
reduces symptoms of disease, the perceived tolera-
bility of the medication in terms of side effects, and
discomforts or complexities of medication use [14–
16].
So as not to simplify matters, the causal predic-
tors of medication adherence is not always so
straight- forward. For example, an important mod-
erator of treatment adherence is a patient’s eng-
agement with their clinician with regards to the
treatment plan, which can foster an understanding
of correct medication use and an awareness of the
impact of medication adherence on treatment out-
comes. When adequately informed, patients may be
less likely to interrupt or discontinue their therapy
[17,18]. Moreover, others have shown that psychi-
atric comorbidities, particularly depression and
cognitive dysfunction, are signiﬁcant predictors of
noncompliance among patients on dermatologic,
antiviral, and psychoactive medications [19–22].
Nonadherence when due to either lack of knowl-
edge or impaired mental function might best be con-
sidered a result of “decisional impairment.” In such
situations, TS-M alone may inadequately or incon-
sistently account for observed variation in adher-
ence behavior.
A ﬁnal observation is that in the literature terms
such as persistence, adherence, and medication
compliance are often used interchangeably and
loosely deﬁned. Deﬁnitional precision in this area is
important, because these terms appear to represent
somewhat distinct sets of inconsistent medication
behavior. Moreover, the various behavioral patterns
of nonadherent or nonpersistent use (e.g., erratic
use, incorrect administration, consistent but partial
dosing, temporary discontinuation, and permanent
discontinuation) may result from somewhat differ-
ent causes.
A Decisional Balance Model of  Treatment Satisfaction
In the Decisional Balance Model of Treatment Sat-
isfaction, decisions affecting adherence are inﬂu-
enced by individuals’ value-weighted judgment of
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positive and negative attributes of treatment.
Among most patient groups the attribute of highest
value is typically the perceived ability of treatment
to mitigate the harms of untreated illness [23], while
side effects, discomforts, and inconveniences are
less heavily weighted. This would be expected
because the need to treat illness is the primary driver
of medication-related behavior; a necessity, which if
met, allows patients to tolerate fairly burdensome
side effects and inconvenient administration
requirements. This may not always be the case,
however, for example, when medication is taken to
prevent a disease (e.g., a statin to control choles-
terol) the risk of immediate illness may perceived to
be low and thus treatment effectiveness would
receive a lower value weighting than would the tol-
erability of side effects and inconveniences of med-
ication use [5].
Consistent with a central premise of Expectancy
Value Theory [12], an individuals’ level of satisfac-
tion with more important medication attributes will
impact medication adherence to a greater extent
than would satisfaction or dissatisfaction with a less
important attributes of a medication. Thus, the
important task of predicting adherence behavior is
often hindered by the difﬁcult task of accounting for
value differences across individuals. Such difﬁculties
contribute to imprecision in predictive models of
medication adherence [2] and may help explain the
difﬁculties many clinicians have at estimating a
patient’s level of compliance in the clinical setting
[24,25].
Figure 1 depicts a hierarchical Decisional Bal-
ance Model of Treatment Satisfaction and medica-
tion adherence decisions based on patients’ implicit
valuation of three speciﬁc medication attributes.
The model suggests that overall TS-M, as well as
resulting adherence behavior, is determined by
patients’ judgment of whether the positive value of
treatment outweigh the negative value-associated
harms and inconveniences of medication use. The
relative values associated with these three attributes
are not ﬁxed across all patients and are inﬂuenced
by numerous factors, as described throughout our
review. Because they are not ﬁxed weights across
individuals, the use of any statistical estimate will
perform more poorly than use of patients’ own rat-
ing of overall value. Thus, ratings of Overall Satis-
faction are sought from respondents to allow them
to individually account for their own unique set of
values. Moreover, the Decisional Balance Model
predicts that an overall TS-M rating would be a
better predictor of medication adherence than any
speciﬁc TS-M dimensions (e.g., Effectiveness, Side
Effects or Convenience). Of note, not all speciﬁc
attributes of a medication may be inﬂuential in
determining the balance of Overall Satisfaction,
some attributes may only become relevant when
they reach a tolerability or inconvenience “thresh-
old” [26].
Using a cross-sectional study design, Atkinson
et al. [2] found that the regression weights associ-
ated with models using the speciﬁc TSQM subscales
(i.e., Effectiveness, Side Effects, and Convenience)
to “predict” Overall Satisfaction scores differed
according to illness condition, medication type, and
the degree of perceived threat associated with the
illness. Moreover, patients’ Overall Satisfaction
rating was a better “predictor” of ratings of their
“likelihood to continue/discontinue using their
medication” than were ratings on the more speciﬁc
Effectiveness, Side Effects or Convenience TSQM
scales. This observation was true irrespective of ill-
ness group or medication type.
Figure 1 A Decisional Balance Model of
Treatment Satisfaction depicting dimensions
of treatment experience that are weighted
to predict overall satisfaction and medica-
tion persistence.
Experience of
Treatment
Effectiveness
Satisfaction Balance
Patient’s Decision to Continue or Change
Experience of
Side Effects
Difficulty or
Inconvenience
of Use
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Among those with chronic conditions, low antic-
ipation of an effective cure may act to reduce the
value weight associated with medication effective-
ness, thereby tipping the decisional balance toward
the negative attributes of the medication such as
ongoing side effects and inconvenience of long-term
use. This may help explain why up to one half of
patients with chronic illness end up making medi-
cation-related decisions, without seeking medical
advice, and become nonadherent [27]. Over time,
because greater emphasis is placed on dissatisfac-
tion with side effects and inconvenience, poorer
adherence may compromise the effectiveness of a
medication, thereby speeding disease progression.
Study Objectives
Two objectives were originally identiﬁed for the cur-
rent study:
• To evaluate the construct validity of a new ver-
sion of the TSQM v. II using structural equation
modeling (SEM), and;
• To examine, posteriori, associations between
respondents’ treatment satisfaction, dosing
adherence and medication persistence.
Methods
Sample and Research Design
Pharmacists at 14 outpatient pharmacies in Michi-
gan agreed to participate in, and recruit participants
for, a 4-week study of consumers’ satisfaction with
a new medication. Study enrollment involved a roll-
ing recruitment of any person, without respect to
medical condition, who came to the pharmacy to ﬁll
a prescription for a medication they had never used
before. Subjects had to be at least 18 years old,
speak English, and consent to study participation.
Participants were paid $25 USD for their involve-
ment in the study. This study was implemented with
approval of the University of Michigan Institutional
Review Board and an HIPAA compliance ofﬁcer.
Consenting participants were given the option of
completing the study survey materials either on the
Internet or by hard copy paper forms. They were
asked to complete one set of questionnaires before
beginning their medication regimen (Time 1) and
another set of forms 4 weeks later (Time 2). At
baseline, the questionnaires gathered information
about the type of medication, type of illness, level of
information they obtained regarding their medica-
tion, demographics, insurance status, and their
anticipations/expectations with respect to the new
medication. The 4-week follow-up questionnaires
gathered information about participants’ experi-
ence with their illness and medication (e.g., severity,
duration, difﬁculty of use); their satisfaction on the
Effectiveness, Side Effects, Convenience of use, and
Overall Satisfaction scales of TSQM v. I and v. II
candidate items; their adherence over the past
month and their intent to continue using the medi-
cation in the future.
Psychometric and Statistical Methods
An initial Principal Components Exploratory Fac-
tor Analysis was performed using all original
TSQM items and the newly reworded candidate sat-
isfaction items. The best performing and conceptu-
ally true items were used to create revised scales for
the TSQM v. II. Typical statistical parameters were
used to evaluate item and scale performance,
including factor loadings, internal consistency, dis-
tributional skew, and ﬂoor-ceiling effects.
Structural equation modeling (SEM) was used to
conﬁrm the hierarchical factor structure of the
TSQM v. II. SEM is a class of statistical methods
used to model the hypothetical relationships
between observed and latent variables. The struc-
tural model to be tested is prespeciﬁed by deﬁning
the relationships among the variables and then
tested by examining the ﬁt between the speciﬁed
model and the correlation or covariance patterns
that are actually observed in the data sets. If the
proposed model ﬁts the observed data, it is said to
be conﬁrmed. The SEM software used was MX, a
public domain application that is available for
download from http://opal.vcu.edu/html/mx/
mxhomepage.html. MX development is supported
by an NIH grant (RR08123) and is provided
through the Department of Psychiatry at the Med-
ical College of Virginia [28].
Three broad criteria were used to judge the sta-
tistical signiﬁcance and substantive meaning of the
theoretical model. The ﬁrst criterion involved global
ﬁt measures (RMSEA, CFI, NFI, chi-square). The
second criterion was the statistical signiﬁcance of
individual parameter estimates for the paths in the
model, computed by dividing the parameter esti-
mates by their respective SE (compared with a t-
value of 1.96 at the 0.05 level of signiﬁcance). The
third criterion considered the magnitude and direc-
tion of the parameter estimates.
The performance of both the original TSQM v. I
and the TSQM v. II was evaluated by comparing the
predictive power of speciﬁc TSQM scales with
respect to respondents’ Overall Satisfaction ratings
as well as reports of actual and anticipated medica-
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tion-related behavior (e.g., adherence, persistence,
and likelihood to use the medication again).
Study Results
A total of 420 usable surveys were completed and
returned by patients just before beginning their
medication, with 342 of these also returning mate-
rials from the week 4 follow-up—resulting in a
study completion rate of 81.4%. The demographic
characteristics of participants completing the study
using either the paper- (n = 248) or Web-based
(n = 94) data collection methods are shown in
Table 1. Overall, the mean age was 49.9 (SD 16.2)
years with an age range of 18 to 88 years. There
were roughly equal proportions of respondents in
the low to middle household income levels, with
fewer in the two highest income categories. The
mean reported income, taking into account family
size, was about $24,500 (SD $15.4 k). The sample
was predominantly white people (∼87%) with the
other 13% being divided between African Ameri-
cans, Native Americans, Hispanics, and Asian
Americans. Those completing the study were some-
what older than the noncompleters (49.9 vs.
43.3 years, P < 0.001). No other differences were
found between completers and noncompleters by
race, education level or household income.
With respect to the method of data collection, the
online group was slightly younger than those
returning paper forms, 40 years (SD 12.6) versus
54 years (SD 16.0) (P < 0.001). A chi-square test
also identiﬁed a signiﬁcant gender difference be-
tween the collection methods (P = 0.02) with a
greater proportion of females completing the paper
surveys than males. Chi-square tests revealed no sig-
niﬁcant differences in the proportion of white peo-
ple and African Americans using the online versus
paper survey. On average, online responders tended
to be better educated and have a greater household
income than paper only responders (P < 0.001). An
interesting observation was that all online respond-
ents had at least a high school diploma.
Descriptive statistics for the key medication and
illness characteristics of the sample are shown in
Table 2. Conforming to what would be expected
from a community sample, the average perceived
symptom burden scores for the condition(s) being
treated by the new medication was fairly low and
the respondents’ perception of their ability to cope
with past side effects of previous medications was
quite high. Participants, on average, indicated they
were taking two other medications concurrently
and were being treated for approximately two addi-
tional illness conditions. The vast majority of con-
sumers in this study (93%) was required to take the
new medication at least once a day and took this
medication in an oral or topical form.
The sample was evenly divided between consum-
ers being treated for chronic versus acute condi-
Table 1 Sample demographics
Paper survey
(n = 248)
Used online
only (n = 94)
Total sample 
survey (n = 342)
Age
Mean (SD) 53.6 (15.9) 40.1 (12.6) 49.9 (± 16.2)
Sex
Male: female 1:2 1:1.2 1:2.1
Family size
Mean (SD) 2.31 (±1.2) 2.7 (±1.2) 2.42 (±1.2)
Median and range 2 (1–6) 3 (1–6) 2.0 (1–6)
Race
White people 217 (87.9%) 81 (86.2%) 298 (87.4%)
African American 14 (5.7%) 3 (3.2%) 17 (5%)
Hispanic 7 (2.8%) 0 (0%) 7 (2.1%)
Native American 9 (3.6%) 1 (1.1%) 10 (2.9%)
Other 7 (2.8%) 9 (9.5%) 9 (2.6%)
Household income ($)*
<25,000 70 (29.4%) 13 (14.1%) 83 (25.2%)
25,000–49,999 62 (26.1%) 18 (19.6%) 80 (24.2%)
50,000–74,999 57 (23.9%) 21 (22.8%) 78 (23.6%)
75,000–99,999 24 (10.1%) 22 (23.9%) 46 (13.9%)
≥100,000 25 (10.5%) 18 (19.6%) 43 (13.1)%
Education
No high school diploma 21 (8.5%) – 21 (6.2%)
High school graduate 66 (26.7%) 5 (5.3%) 71 (20.8%)
Some college 75 (30.4%) 32 (34.0%) 107 (31.4%)
College graduate 47 (19.0%) 27 (28.7%) 74 (21.7%)
Postgraduate study 38 (15.4%) 30 (31.9%) 68 (19.9%)
*Adjusted for number of dependents living at home.
Atkinson et al.S14
tions, as a result, the numbers of respondents who
were unsure about how long they would need to
take the medication was equal to those taking med-
ication for a delimited time period. At week 4, 95
(29%) had completed their course of medication.
The mean self-reported adherence level after a
month of using the new medication was high (9 out
of 10). Only 34 (10%) study participants indicated
that they had stopped therapy prematurely, the
majority stopped as a result of lack of medication
effectiveness, followed by problematic side effects
and then inconvenience.
TSQM Version II: Content Modiﬁcations and 
Item Reduction
New item content for the TSQM v. II was based on
respondents’ feedback during earlier studies using
the TSQM v. I. Suggestions were made about the
“mental side effects” and “ease of use” items in the
original instrument, and speciﬁcally: 1) The TSQM
should ask about the impact of medication on emo-
tional functioning, not just mental side effects; and
2) A question should be added to assess satisfaction
with frequency of use. Changes were also made to
the item stems of ﬁve other questions to make their
wording more consistent with the “satisfaction or
dissatisfaction” stems used for other items in the
instrument.
A principal components factor analysis (w/var-
imax rotation), involved all the proposed speciﬁc
items in the TSQM v. II item pool (see Table 3),
and resulted in the expected three factors
(Eigenvalues > 1.0) that explained over 78% of the
total pooled variance.
As a result of this factor analysis one Side Effect
item was dropped because of poor factor loading.
This item made reference to the impact of side effects
on overall satisfaction and was not consistent with
the other Side Effect items that addressed the symp-
tom basis for dissatisfaction. A second item was also
dropped from the Side Effects scale that asked about
the “bothersomeness” of side effects. Although a
sufﬁcient Side Effects factor loading was found, ear-
lier questions were raised during translation activi-
ties associated with the TSQM v. I about the
meaning of “bothersomeness” in other non-English-
speaking cultures and the cross-cultural adaptation
of the concept proved difﬁcult.
Table 2 Descriptive statistics of medication and illness characteristics
Characteristics of  
treatment and illness Response Frequency (%)
Medication dosage form Oral 286 (84%)
Topical 37 (11%)
Inhalable 12 (4%)
Injectable 5 (1%)
Other 2 (<1%)
Duration of prescription Less than a week 31 (13%)
1–2 weeks 69 (29%)
2–3 weeks 14 (6%)
1–2 months 24 (10%)
>2 months 98 (42%)
Frequency of use Several × daily 150 (46%)
Once a day 168 (51%)
Several × a week 6 (2%)
Once a week 2 (<1%)
>1 × a week 1 (<1%)
Medication status at 4 weeks Therapy ﬁnished 95 (29%)
Therapy ongoing 202 (61%)
Discontinued due to:
Ineffective 21 (6%)
Side effects 10 (3%)
Inconvenient 3 (1%)
Nature of disease Chronic 150 (46%)
Acute 156 (48%)
Unknown 21 (6%)
Mean (±SD) Minimum score Maximum score
Mean adherence 4.55 (±0.57) 1 (Low adherence) 5 (High adherence)
Coping with side effects of medications 3.88 (±0.96) 1 (Not coping) 5 (Cope very well)
No. concomitant medications 2.51 (±3.06) 0 20
General attitudes toward medication 3.76 (±1.04) 1 (–) Attitude 5 (+) Attitude
Illness/symptom burden score 1.99 (±0.87) 1 (Low burden) 5 (High burden)
Comorbidities Median = 1.6 0 14
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An Effectiveness item that asks about “the time it
takes for the medication to start working” was also
dropped because it was thought to have different
meanings in different treatment contexts. Transla-
tion consultants made a suggestion that assessment
of satisfaction with a pain medication (for example)
using this item would have a very different meaning
if the respondent were taking an antidepressant.
Another item that was dropped from the Con-
venience scale asked generally about the “conven-
ience” of taking a medication, while other items on
the same scale ask about more speciﬁc causes of dis-
satisfaction (i.e., frequency of dosing, effort to plan,
and difﬁculty of administration). While the general
convenience item loaded strongly, it was thought
that the more speciﬁc items adequately covered the
construct of Convenience. In addition, some consid-
eration was given to the relatively weak loading of
the “difﬁculty of administration item” on the Con-
venience scale. It was not dropped, however,
because the vast majority of respondents in this
study were on medications in pill form. This current
sample characteristic may have resulted in a some-
what weaker loading on the factor than would be
observed in studies employing a more heterogene-
ous sampling of administration methods.
Finally, the Overall Satisfaction item “Conﬁ-
dence that the medication is a good thing” was
dropped because it asked respondents about their
conﬁdence in their evaluation and not speciﬁcally
for a judgment rating.
As later results will show, removal, addition, and
reﬁnement of the various TSQM items did not
appear to result in signiﬁcant performance differ-
ences between the two versions of the instrument.
For reference purposes, Table 4 presents items of
the TSQM v. I and the item pool that was consid-
ered for the TSQM v. II. Full versions of the TSQM
can be found in Appendices A and B.
TSQM Version II: Scale Characteristics and 
Construct Validity
For the reasons stated various items were removed
and the remaining eight speciﬁc items (i.e., address-
ing Effectiveness, Side Effects, and Convenience;
TSQM v. I items 1, 2 and items 6, 7, 9, 10 with
modiﬁed stems; along with the two new items
addressing emotional side effects and frequency of
administration) were reanalyzed. The ﬁnal factor
analysis converged in six iterations and the three
factors (i.e., Effectiveness, Side Effects, and Conven-
ience of Use) explained 88.3% of the total pooled
variance with Eigenvalues greater than 1.3 (see
Table 5).
Table 6 presents the intercorrelations between
items in versions I and II of the TSQM. The bolded
correlations highlight the associations between the
ﬁve items that were reworded in version II to use a
dissatisfaction stem. The rectangular boxes group
correlations by the TSQM scale constructs (Effec-
tiveness, Side Effects, Convenience, and Overall
Satisfaction).
Tables 7 and 8 present item and scale statistics
for both versions of the TSQM. No major differ-
ences were observed between the two versions with
one exception. The Side Effects scale in version I
had a lower proportion of individuals at the ceiling
of the scale than version II (i.e., the proportion of
individuals with scores of 100 on a scale from 0 to
100). This may have been due to differences in the
stem wording between the two versions. Version I
asked about symptom levels while version II asked
about dissatisfaction regarding symptom levels. It
appears that approximately 13% of respondents
reported side effects on version I that did not cause
them any appreciable dissatisfaction.
TSQM Version II Hierarchical Conﬁrmatory 
Factor Analyses
Figure 2  depicts  a  diagrammatic  representation
of the conﬁrmatory factor analysis (CFA) of
the TSQM v. II based on the Decisional Balance
Model of Treatment Satisfaction. Global measures
of goodness of model ﬁt were evaluated. The chi-
square statistic was not signiﬁcant (chi-square
value = 18.65, d.f. = 19, P = 0.46), indicating the
model ﬁt the data. The root-mean-square error of
approximation (RMSEA) was virtually zero (90%
Table 3 Initial factor solution with all proposed items for
version II of the TSQM
TSQM version II items
Factors
I II III
Effectiveness
Preventing or treating condition 0.17 0.15 0.93
Relief of symptoms 0.17 0.16 0.94
Time to start working (dropped) 0.05 0.17 0.89
Side effects
Interference w/physical function 0.89 0.00 0.17
Interference w/mental function 0.90 0.03 0.17
Interference w/mood or emotions
Bothersomeness of side effects (dropped)
0.87
0.88
0.05
0.03
0.18
0.19
Side effects impact on overall satisfaction 
(dropped)
0.46 0.06 −0.20
Convenience
Ease of medication use −0.07 0.79 0.18
Planning for medication use 0.07 0.92 0.11
Frequency of medication use 0.05 0.89 0.15
Convenience of medication use (dropped) 0.10 0.91 0.04
Eigenvalues 4.57 3.0 1.9
Proportion of variance explained (%) 38.1 24.7 15.8
Atkinson et al.S16
conﬁdence interval [CI], 0.000–0.046) and, being
less than 0.05, also indicated a good ﬁt. Both the
comparative ﬁt index (CFI) value of 0.98 and the
non-normed ﬁt index (NNFI) value of 0.918
exceeded 0.90, suggesting a model with adequate
ﬁt. Overall, this set of ﬁve key global statistics
conﬁrmed that the proposed model ﬁt the data
well.
With respect to the model structure, the path
coefﬁcient between Overall Satisfaction and Effec-
tiveness (0.96) was much greater than the weight of
Side Effects on Overall Satisfaction (0.34) or Con-
venience (0.36), with Side Effects and Convenience
loading equally Overall Satisfaction. The Side
Effects dimension exhibited some measurement dis-
turbance because the residual estimate for this
latent variable could not be ﬁxed at 1.00 without
compromising the ﬁt of the entire model. Allowing
the parameter to ﬂoat and to be estimated by the
SEM software, the residual was estimated to be
0.40. This observation may be due to the fact that
only 25% of the sample reported experiencing any
side effects, thus inﬂuencing the overall structural ﬁt
of Overall Satisfaction on the three latent variables
on Overall Satisfaction.
Table 4 Comparison of items in version I and version II of the TSQM
Original TSQM TSQM version II
1. How satisﬁed or dissatisﬁed are you with the ability of the 
medication to prevent or treat your condition?
Same: How satisﬁed or dissatisﬁed are you with the ability of the 
medication to prevent or treat your condition?
2. How satisﬁed or dissatisﬁed are you with the way the medication 
relieves your symptoms?
Same: How satisﬁed or dissatisﬁed are you with the way the 
medication relieves your symptoms?
3. How satisﬁed or dissatisﬁed are you with the amount of time it 
takes the medication to start working?
Dropped
4. As a result of taking this medication, do you currently experience 
any side effects at all?
Same: As a result of taking this medication, do you currently 
experience any side effects at all?
5. How bothersome are the side effects of the medication you take 
to treat your condition?
Dropped
6. To what extent do the side effects interfere with your physical 
health and ability to function (i.e., strength, energy levels, etc.)?
Reworded: How dissatisﬁed are you by side effects that interfere 
with your physical health and ability to function (e.g., strength, 
energy levels)?
7. To what extent do the side effects interfere with your mental 
function (i.e., ability to think clearly, stay awake, etc.)?
Reworded: How dissatisﬁed are you by side effects that interfere 
with your mental function (e.g., ability to think clearly, stay awake)?
New: How dissatisﬁed are you by side effects that interfere with 
your mood or emotions (e.g., anxiety/fear, sadness, irritation/anger)?
8. To what degree have medication side effects affected your overall 
satisfaction with the medication?
Dropped
9. How easy or difﬁcult is it to use the medication in its current 
form?
Reworded: How satisﬁed or dissatisﬁed are you with how easy the 
medication is to use?
10. How easy or difﬁcult is it to plan when you will use the 
medication each time?
Reworded: How satisﬁed or dissatisﬁed are you with how easy it is 
to plan when you will use the medication each time?
New: How satisﬁed or dissatisﬁed are you by how often you are 
expected to use/take the medication?
11. How convenient or inconvenient is it to take the medication as 
instructed?
Dropped
12. Overall, how conﬁdent are you that taking this medication is a 
good thing for you?
Dropped
13. How certain are you that the good things about your medication 
outweigh the bad things?
Reworded: How satisﬁed are you that the good things about this 
medication outweigh the bad things?
14. Taking all things into account, how satisﬁed or dissatisﬁed are 
you with this medication?
Same: Taking all things into account, how satisﬁed or dissatisﬁed are 
you with this medication?
Table 5 Final factor solution of the content speciﬁc items
of the TSQM version II
TSQM version II items
Factors
I II III
Effectiveness
Preventing or treating condition 0.16 0.14 0.96
Relief of symptoms 0.15 0.15 0.96
Side effects
Interference w/physical function 0.88 0.02 0.14
Interference w/mental function 0.94 0.03 0.14
Interference w/mood or emotions 0.91 0.05 0.14
Convenience
Planning required for medication use 0.06 0.93 0.15
Frequency of medication use 0.05 0.93 0.13
Ease of medication use −0.01 0.89 0.13
Eigenvalues 3.4 2.3 1.3
Proportion of variance explained (%) 31.7 32.0 24.6
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The Comparative Performance of  Versions I and II 
of the TSQM
Table 9 compares the predictive power of the two
versions of the TSQM based on regression analyses,
using various aspects of satisfaction and adherence
as dependent measures, speciﬁcally; Overall Satis-
faction, participants’ willingness to take the medi-
cation again, frequency of forgetting to take the
medication, taking less medication than prescribed
because of feeling better, and taking less medication
than prescribed because they felt worse. The con-
current validity estimates and performance of both
Table 6 Correlations between items in versions I and II of the TSQM
TSQM version II 
TSQM version I
Prevents or
treats
Relieves
symptoms
Physical 
function Mental Mood
Ease of 
use
Effort to 
plan
How often
used
Good vs.
Bad
All
things
Effectiveness
Prevents or treats – 0.94 0.30 0.32 0.31 0.24 0.25 0.28 −0.71 −0.71
Relieves symptoms 0.94 – 0.30 0.32 0.32 0.26 0.26 0.29 −0.69 −0.72
Time to start working 0.81 0.84 0.19 0.19 0.20 0.25 0.27 0.29 −0.59 −0.62
Side effects
Bothersome side effects 0.25 0.25 0.82 0.69 0.73 −0.01 0.06 0.04 −0.37 −0.33
Interfere physical function 0.30 0.30 0.87 0.74 0.68 0.06 0.09 0.06 −0.39 −0.37
Interfere mental function 0.21 0.20 0.62 0.74 0.62 0.07 0.10 0.10 −0.28 −0.27
SE impact on satisfaction −0.05 −0.06 0.26 0.29 0.24 −0.01 0.06 0.02 0.07 0.05
Convenience
Easy to use 0.15 0.15 0.04 0.04 0.07 0.72 0.41 0.38 −0.17 −0.13
Plan when to use 0.19 0.17 0.07 0.09 0.13 0.53 0.70 0.57 −0.26 −0.22
Convenient to take 0.20 0.19 0.08 0.07 0.12 0.61 0.62 0.58 −0.27 −0.21
Overall
Conﬁdent in beneﬁts −0.74 −0.72 −0.33 −0.27 −0.31 −0.26 −0.30 −0.28 0.80 0.66
Good outweighs the bad −0.69 −0.65 −0.29 −0.22 −0.29 −0.33 −0.31 −0.30 0.78 0.64
All things into account −0.71 −0.72 −0.39 −0.34 −0.34 −0.26 −0.30 −0.33 0.67 –
Table 7 Item statistics of TSQM version II (n = 339)
TSQM scale 
and items
Item means (SD)
before 
transformation
Item-scale
correlations*
Item correlation
with overall
satisfaction scale*
Effectiveness
Prevents or treats condition 2.82 (1.4) 0.98 0.77
Relieves symptoms 2.88 (1.4) 0.98 0.77
Side effects
Interferes w/physical health 1.34 (0.9) 0.75 0.41
Interferes w/mental function 1.26 (0.7) 0.66 0.34
Interferes with mood 1.27 (0.8) 0.60 0.37
Convenience
Effort to plan 2.15 (1.1) 0.74 0.25
How often used 2.16 (1.1) 0.69 0.31
Ease of use 2.03 (1.1) 0.62 0.33
Overall satisfaction
Good outweighs the bad 3.55 (1.2) 0.88 0.88
Taking all things into account 2.90 (1.6) 0.94 0.94
*All items correlated with Overall Satisfaction at P-value < 0.05.
Table 8 A comparison of scale characteristics between the TSQM v. I and v. II (n = 344)
TSQM version no.
Mean (SD)* No. items Chronbach’s alpha† Skewness statistic % Ceiling
V. I V. II V. I V. II V. I V. II V. I V. II V. I V. II
Effectiveness 68.23 (22.7) 69.00 (23.7) 3 2 0.95 r = 0.94§ −0.91 −0.85 9.0 8.2
Side effects‡ 90.38 (19.7) 93.58 (15.9) 4 3 0.88 0.91 −2.68 −2.88 74.0 76.7
62.26 (21.6) 74.11 (22.8) −0.54 −0.85 6.7 20.4
Convenience 85.04 (16.2) 81.39 (17.1) 3 3 0.81 0.91 −0.73 −0.84 36.7 30.6
Overall satisfaction 63.79 (26.2) 72.08 (21.4) 3 2 0.88 r = 0.88§ −0.73 −0.78 10.2 14.3
*Scoring algorithms provide transformed scores between 0 and 100, these are presented along with the two versions of the TSQM in Appendices A and B.
†Assessment of internal consistency is not computable with one item missing.
‡The scale mean, skew, and ceiling statistics are reported for the total sample as well as the subsample reporting any medication side effects (n = 85).
§This statistic is not computable for scales employing two items, Spearman’s correlation coefﬁcients are used to approximate the strength of item association.
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instruments were equivalent, with only slight differ-
ences in the statistical signiﬁcance of scale Beta
weights across analyses.
Overall Satisfaction scores were strongly pre-
dicted by all three speciﬁc TSQM v. II scales (Effec-
tiveness, Side Effects, and Convenience), with Side
Effects and Effectiveness scores being the strongest
predictors. Participants’ willingness to take their
medication again was predicted predominantly by
Overall Satisfaction, and less so by the Side Effects
subscale. Respondents’ who reported inconsistent
medication use were less strongly predicted by this
TSQM scale using either version of the instrument.
Completers versus Discontinuers
A ﬁnal set of discriminant analyses were conducted
to examine the ability of satisfaction scores to cor-
rectly classify those who completed their course of
medication and those who did not (Table 10).
Although both models were signiﬁcant, the Discrete
Satisfaction Model, consisting only of the three spe-
ciﬁc treatment satisfaction scales, demonstrated sig-
niﬁcantly less positive predictive power than the
hierarchical Decisional Balance Model. These ﬁnd-
ings support the underlying premise of model, that
the Overall Satisfaction is the strongest predictor of
true cases of medication discontinuation.
Discussion
The psychometric performance of the new version
of the TSQM is equivalent to the TSQM v. I, with
the advantages of it being shorter and more consist-
ently worded. Comparisons using results from the
various regression analyses suggest that both ver-
sions perform equivalently when predicting meas-
ures of concurrent validity (i.e., patients’ willingness
to take the medication again, and various self-
reported indicators of nonadherence). Moreover,
results of the CFA provide fairly convincing evi-
dence that the TSQM v. II precisely measures the
dimensions described in the Decisional Balance
Model of Treatment Satisfaction, on which both
version of the instrument are based. Some distur-
bance in the model’s Side Effects variable was
observed, however, which suggests a need for more
in-depth study of persons experiencing side effects.
Only 25% of respondents in the current study expe-
rienced any side effects and the disturbance in the
CFA model may have been in part due to distribu-
tional skew toward the highly satisﬁed range.
The loadings of the Effectiveness, Side Effects,
and Convenience latent factors on the super-ordi-
nate Overall Satisfaction factor support the hierar-
chical construct organization of the measure and
the model provides a way to test predictions regard-
Figure 2 A hierarchical conﬁrmatory factor analysis of the TSQM version II.
Physical
Mental
Mood
Effectiveness
  Convenience
Side
Effects
Overall 
Satisfaction
Prevent
 Relieve
To plan
 How often
 How easy
   Appears OK   ML ChiSq
Group Fit: 18.6495
Fits 18.649 (19.000, 32.978)
Probability 0.480
AIC -19.351 (-19.000, -5.022)
RMSEA 0.000 (0.000, 0.046)
Degrees of freedom 19
Free parameters 17 
Observed Statistics 36
Constraints 0
0.25
0.98
0.03 1.00
0.14
0.94
1.00
0.99
0.96
 Fix 1.0
Fix 1.0
0.98
0.84
0.36
1.00
0.40
0.34
  Fix 1.0
0.14
0.11
0.21
0.16
0.37
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Table 9 A performance comparison of the TSQM versions I and II
Dependent criteria
TSQM predictors of dependent criteria R2 for the
regression
model CommentsTSQM version I TSQM version II
Overall satisfaction 
rating
Effectiveness:
0.63 (0.03), P < 0.000001
Side effects:
0.30 (0.04), P < 0.000001
Convenience:
Effectiveness:
0.62 (0.03), P < 0.000001
Side effects:
0.33 (0.05), P < 0.000001
Convenience:
70% vs. 70% The standardized beta weight for each scale, 
reﬂects the importance of that dimension 
(Effectiveness, Side Effects, and 
Convenience) and its impact on overall 
satisfaction with medication
0.13 (0.04), P < 0.001 0.11 (0.04), P < 0.005
Would you take it 
again?
Effectiveness:
0.03 (0.05), n.s.
Side effects:
0.10 (0.06), P = 0.06
Convenience:
0.07 (0.04), P = 0.09
Effectiveness:
0.05 (0.05), n.s.
Side effects:
0.14 (0.06), P < 0.01
Convenience:
−0.002 (0.04), n.s.
60% vs. 60% Willingness to take the medication again, 
seemed to perform as a proxy for overall 
ratings of satisfaction with medication, 
possibly supporting a common appreciation 
of the relationship between satisfaction and 
future planning of medication-related 
behaviorOverall: Overall:
0.68 (0.06), P < 0.000001 0.67 (0.06), P < 0.000001
How often did you 
forget to take 
your medication?
Effectiveness:
−0.02 (0.08), n.s.
Side effects:
−0.14 (0.06), P < 0.05
Effectiveness:
0.002 (0.06), n.s.
Side effects:
−0.12 (0.07), P = 0.09
8% vs. 9% Convenience of use was the best predictor of 
the frequency with which respondents’ 
forgot to take their medication
Convenience: Convenience:
−0.30 (0.05), P < 0.000001 −0.31 (0.05), P < 0.000001
Overall: Overall:
0.17 (0.09), n.s. 0.16 (0.08), P < 0.05
Took less because 
felt better
Effectiveness:
0.14 (0.06), P < 0.05
Side effects:
−0.16 (0.07), P < 0.02
Effectiveness:
0.16 (0.06), P < 0.01
Side effects:
−0.14 (0.07), P < 0.05
5% vs. 6% Similarly, Convenience predicted taking less 
because they felt better, perhaps due 
reengagement with a busy life and the 
inconvenience of repeated dosing
Convenience: Convenience:
−0.18 (0.05), P < 0.001 −0.20 (0.05), P < 0.0002
Overall: Overall:
−0.09 (0.08), n.s. −0.09 (0.07), n.s.
Took less because 
felt worse. 
Included only 
those indicating 
they had side 
effects (n = 88)
Effectiveness:
0.125 (0.04), P < 0.01
Side effects:
−0.33 (0.05), P < 0.000001
Effectiveness:
0.14 (0.04), P < 0.001
Side effects:
−0.32 (0.05), P < 0.000001
26% vs. 23% Quite a large amount of the variance in 
medication adherence was explained by 
participants’ dissatisfaction with the side 
effects of their medication
Convenience: Convenience:
−0.18 (0.04), P < 0.00001 −0.10 (0.04), P < 0.01
Overall: Overall:
−0.18 (0.05), P < 0.001 −0.20 (0.05), P < 0.0001
n.s., not signiﬁcant.
Table 10 Prediction of medication persistence using two models of treatment satisfaction
Model Variable Wilks’ lambda F-value P-value
Discrete Effectiveness 0.861 0.000001
satisfaction model Side effects 0.808 0.000001
Convenience 0.751 0.66
Total model 0.751 F3,339 = 37.5 P < 0.0001
Predicted/actual 
discontinued: 14/34 = 41%
Predicted/actual 
persisted: 302/309 = 98%
False positives: 20/34 = 59% False negatives: 7/309 = 2%
Hierarchical 
decisional 
balance model
Effectiveness
Side effects
Convenience
0.653
0.665
0.658
0.62
0.01
0.11
Overall satisfaction 0.751 0.000001
Total model 0.653 F3,338 = 44.9 P < 0.00001
Predicted/actual Predicted/actual 
discontinued:  24/34 = 71% persisted: 300/310 = 97%
False positives: 10/34 = 28% False negatives: 10/310 = 3%
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ing patient medication adherence. As expected,
given that the primary reason for taking a medica-
tion is illness cure/prevention or symptom relief, the
loading of the Effectiveness variable on Overall
Satisfaction was strongest. Side Effects and Con-
venience were about equally loaded on Overall
Satisfaction suggesting, in this sample, an equal
impact of these medication attributes on Overall
Satisfaction.
Finally, evaluation of the importance of a hierar-
chical Decisional Balance Model was demonstrated
using discriminant analysis. The use of speciﬁc
dimensions of satisfaction with medication
attributes (i.e., Effectiveness, Side Effects and Con-
venience) to identify individuals who discontinued
medication use was not nearly as strong as a model
that included participants’ evaluation of their Over-
all Satisfaction (41% vs. 71% correct classiﬁcation
or positive predictive value to predict nonpersistent
individuals). The power of the hierarchical model
was particularly impressive given that only about
10% of individuals in the total sample were non-
persistent. Granted, because treatment satisfaction
measures at week 4 were administered after discon-
tinuation, the predictive validity of this model needs
to be assessed using a prospective research design.
Nevertheless, there is little reason to believe that
TSQM measurements at week 4 would differ signif-
icantly from respondent ratings of dissatisfaction
just before discontinuation of the medication.
Limitations of the Current Study and Future Directions
Various limitations with respect to study design and
sample selection may have impacted the psychomet-
ric parameter estimates and the generalizability of
results: 1) the short study duration may have trun-
cated the sampling frame (right censoring persist-
ence data) and affected the frequency and reasons
for discontinuations (e.g., discontinuations due to
loss of medication ineffectiveness); 2) the simulta-
neous measurement of TS-M and dosing adherence
and persistence with medication over time, may
have introduced some response consistency due to
recall bias, increasing the observed correlation
between satisfaction and self-reported adherence
and persistence. More detailed prospective studies
are needed in which TS-M data are collected regu-
larly over time and can be used to temporally
predict discontinuation (nonpersistence) or nonad-
herence with the medication regimen before they
occur; 3) resulting from the select outpatient sam-
ples, caution must be used when using the current
scale statistics and CFA to estimate sample param-
eters for other studies. For example, in other
research involving patients with chronic illness, sat-
isfaction with Side Effects appeared to weigh more
heavily on judgments of Overall Satisfaction than
did Convenience; and 4) the low incidence of side
effects made it difﬁcult to precisely ﬁt the Side
Effects latent variable within the conﬁrmatory SEM
model, without allowing for some measurement dis-
turbance. Moreover, it is less than ideal that the
conﬁrmatory SEM analysis was conducted using
observed variables that had been preselected based
on earlier EFA results. As a result, additional studies
are required to replicate the hierarchical model and
provide adequate sampling of persons with side
effects to allow for subsample modeling. A ﬁnal
note is that data were not gathered with respect to
patients’ level of difﬁculty with self-administration
of medication—a consideration that might be par-
ticularly important for certain types of delivery
methods among persons with impaired administra-
tion abilities.
Conclusions
This study provides convincing evidence in support
of the reliability and validity of the TSQM v. II. The
hierarchical Decisional Balance Model of Treatment
Satisfaction shows particular promise as a theoret-
ical tool for prediction of treatment dosing adher-
ence and medication persistence over time.
Source of ﬁnancial support: Pharmacia Corp. & Pﬁzer
Inc.
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Appendix A
TSQM (Version I): Treatment Satisfaction 
Questionnaire for Medication
Rights to the TSQM v. I and TSQM v. II are shared
by Quintiles Strategic Research Services and Pﬁzer
Inc. For permission to use approved formatted ver-
sions of the instruments as well as obtaining numer-
ous translations, please contact Shoshana Colman,
PhD, Quintiles Strategic Research Services, 475
Brannan Street, Suite 430, San Francisco, CA
94107; Voice: 415.633.3243; Fax: 415.633.3133;
shoshana.colman@quintiles.com
1. How satisﬁed or dissatisﬁed are you with the
ability of the medication to prevent or treat
your condition?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
2. How satisﬁed or dissatisﬁed are you with the
way the medication relieves your symptoms?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
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6 Very Satisﬁed
7 Extremely Satisﬁed
3. How satisﬁed or dissatisﬁed are you with the
amount of time it takes the medication to start
working?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
4. As a result of taking this medication, do you
experience any side effects at all?
1 Yes
0 No
5. How bothersome are the side effects of the
medication you take to treat your condition?
1 Extremely Bothersome
2 Very Bothersome
3 Somewhat Bothersome
4 A Little Bothersome
5 Not at All Bothersome
6. To what extent do the side effects interfere
with your physical health and ability to func-
tion (i.e., strength, energy levels, etc.)?
1 A Great Deal
2 Quite a Bit
3 Somewhat
4 Minimally
5 Not at All
7. To what extent do the side effects interfere
with your mental function (i.e., ability to
think clearly, stay awake, etc.)?
1 A Great Deal
2 Quite a Bit
3 Somewhat
4 Minimally
5 Not at All
8. To what degree have medication side effects
affected your overall satisfaction with the
medication?
1 A Great Deal
2 Quite a Bit
3 Somewhat
4 Minimally
5 Not at All
9. How easy or difﬁcult is it to use the medica-
tion in its current form?
1 Extremely Difﬁcult
2 Very Difﬁcult
3 Difﬁcult
4 Somewhat Easy
5 Easy
6 Very Easy
7 Extremely Easy
10. How easy or difﬁcult is it to plan when you
will use the medication each time?
1 Extremely Difﬁcult
2 Very Difﬁcult
3 Difﬁcult
4 Somewhat Easy
5 Easy
6 Very Easy
7 Extremely Easy
11. How convenient or inconvenient is it to take
the medication as instructed?
1 Extremely Inconvenient
2 Very Inconvenient
3 Inconvenient
4 Somewhat Convenient
5 Convenient
6 Very Convenient
7 Extremely Convenient
12. Overall, how conﬁdent are you that taking
this medication is a good thing for you?
1 Not at All Conﬁdent
2 A Little Conﬁdent
3 Somewhat Conﬁdent
4 Very Conﬁdent
5 Extremely Conﬁdent
13. How certain are you that the good things about
your medication outweigh the bad things?
1 Not at All Certain
2 A Little Certain
3 Somewhat Certain
4 Very Certain
5 Extremely Certain
14. Taking all things into account, how satisﬁed
or dissatisﬁed are you with this medication?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
SCALE SCORING ALGORITHM: TSQM Scale
scores range from 0 to 100 and no computed score
should be lower or higher than these limits.
EFFECTIVENESS: ([(Item 1 + Item 2 + Item 3) − 3]
divided by 18) × 100
If one item is missing: ([(Sum of Item 1? + Item
2? + Item 3?)) − 2] divided by (12) × 100
SIDE EFFECTS: ([Sum of Item 5 to Item 8) − 4]
divided by 16) × 100
If one item is missing: ([(Sum of Item 5? to Item
8?)) − 3] divided by 12) × 100
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CONVENIENCE: ([Sum of Item 9 to Item 11) − 3]
divided by 18) × 100
If one item is missing: ([(Sum of Item9? to
Item11?)) − 2] divided by (12) × 100
OVERALL SATISFACTION
First recode Item14_recode = (Item14 − 1) × 5/6
Then: ([Sum of Item 12 to Item 14) − 3] divided by
(12) × 100
If any one Item is missing: ([Sum of Item 12? to Item
14?) − 2] divided by (8) × 100
Appendix B
TSQM (Version II):  Treatment Satisfaction 
Questionnaire for Medication
Rights to the TSQM v. I and TSQM v. II are shared
by Quintiles Strategic Research Services and Pﬁzer
Inc. For permission to use approved formatted ver-
sions of the instruments as well as obtaining numer-
ous translations, please contact Shoshana Colman,
PhD, Quintiles Strategic Research Services, 475
Brannan Street, Suite 430, San Francisco, CA
94107; Voice: 415.633.3243; Fax: 415.633.3133:
shoshana.colman@quintiles.com.
1. How satisﬁed or dissatisﬁed are you with the
ability of the medication to prevent or treat
the condition?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
2. How satisﬁed or dissatisﬁed are you with the
way the medication relieves symptoms?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
3. As a result of taking this medication, do you
experience any side effects at all?
1 Yes
0 No
4. How dissatisﬁed are you by side effects that
interfere with your physical health and ability
to function (e.g., strength, energy levels)?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Somewhat Dissatisﬁed
4 Slightly Dissatisﬁed
5 Not at all Dissatisﬁed
5. How dissatisﬁed are you by side effects that
interfere with your mental function (e.g., abil-
ity to think clearly, stay awake)?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Somewhat Dissatisﬁed
4 Slightly Dissatisﬁed
5 Not at all Dissatisﬁed
6. How dissatisﬁed are you by side effects that
interfere with your mood or emotions (e.g.,
anxiety/fear, sadness, irritation/anger)?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Somewhat Dissatisﬁed
4 Slightly Dissatisﬁed
5 Not at all Dissatisﬁed
7. How satisﬁed or dissatisﬁed are you with how
easy the medication is to use?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
8. How satisﬁed or dissatisﬁed are you with how
easy it is to plan when you will use the med-
ication each time?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
9. How satisﬁed or dissatisﬁed are you by how
often you are expected to use/take the
medication?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
10. How satisﬁed are you that the good things
about this medication outweigh the bad things?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
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6 Very Satisﬁed
7 Extremely Satisﬁed
11. Taking all things into account, how satisﬁed
or dissatisﬁed are you with this medication?
1 Extremely Dissatisﬁed
2 Very Dissatisﬁed
3 Dissatisﬁed
4 Somewhat Satisﬁed
5 Satisﬁed
6 Very Satisﬁed
7 Extremely Satisﬁed
SCALE SCORING ALGORITHM: TSQM Scale
scores range from 0 to 100 and no computed score
should be lower or higher than these limits.
EFFECTIVENESS: ([(Item 1 + Item 2) − 2] divided
by (12) × 100
SIDE EFFECTS: ([Sum of Item 4 to Item 6) − 3]
divided by 12) × 100
If one item is missing: ([(Sum of the two completed
items) − 2] divided by (8) × 100
CONVENIENCE: ([Sum of Item 7 to Item 9) − 3]
divided by 18) × 100
If one item is missing: ([(Sum of the two completed
items) − 2] divided by (12) × 100
GLOBAL SATISFACTION: ([Sum of Item 10 to
Item 11) − 2] divided by 12) × 100
